We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EU Inspectors Cite Chinese Manufacturer for Critical Deficiencies

EU Inspectors Cite Chinese Manufacturer for Critical Deficiencies

November 21, 2019

EU investigators found serious deficiencies in aseptic manufacturing during an inspection of the NCPC Hebei Huamin facility in Shijiazhuang, Hebei province.

Inspection officials from Croatia — an EU member state since 2013 — logged 31 deficiencies, including two “critical” and five “major” deficiencies, in the EudraGMDP inspection database.

The two critical deficiencies were in environmental monitoring and the preparation and use of sterile disinfectants for production of antibiotic APIs.

The inspectors found major deficiencies in quality assurance, document control, preparation and handling of sterile packaging material, electronic records and signatures, and manufacturing areas and equipment.

As a result of the violations, the EU barred the drugmaker from supplying cefotaxime sodium, cefuroxime sodium and ceftriaxone sodium pending its compliance with GMP requirements.

View today's stories

Pharmaceuticals Inspections and Audits

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Sanofi-logo.gif

    Sanofi’s Sarclisa Earns Second EC Clearance for Multiple Myeloma

  • emergency use authorization approved

    Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test

  • Withdraws cubes

    Zynteglo Gene Therapy Withdrawn in Germany

  • CE mark

    Empowered Diagnostics Earns CE Mark for Rapid COVID-19 Antigen Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing